U.S. Dermatology Imaging Devices Market Size, Share & Trends Analysis Report By Modality (Digital Photographic Imaging, OCT, Dermatoscope), By Application (Skin Cancers, Inflammatory Dermatoses), By End-use,- Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2033

U.S. Dermatology Imaging Devices Market Size and Research

The U.S. dermatology imaging devices market size was exhibited at USD 815.55 million in 2023 and is projected to hit around USD 2,898.51 million by 2033, growing at a CAGR of 13.52% during the forecast period 2024 to 2033.

U.S. Dermatology Imaging Devices Market Size 2024 To 2033

U.S. Dermatology Imaging Devices Market Key Takeaways:

  • Based on modality, the dermatoscope segment led the market with the largest revenue share of 41.18% in 2023.
  • Based on application, the skin cancer segment led the market with the largest revenue share of 48.24% in 2023.
  • Based on end use, the hospital segment accounted for the largest revenue share of 44.0% in 2023.
  • The dermatology centers segment is expected to experience at a significant CAGR during the forecast period.

Report Scope of U.S. Dermatology Imaging Devices Market

 Report Coverage  Details
Market Size in 2024 USD 925.81 Million
Market Size by 2033 USD 2,898.51 Million
Growth Rate From 2024 to 2033 CAGR of 13.52%
Base Year 2023
Forecast Period 2024-2033
Segments Covered Modality, Application, End use
Market Analysis (Terms Used) Value (US$ Million/Billion) or (Volume/Units)
Country scope U.S.
Key Companies Profiled Caliber Imaging and Diagnosis; Canfield Scientific, Inc.; Clarius; Cortex Technology; Courage+Khazaka electronic GmbH; DermLite; DRAMIŃSKI S. A.; e-con Systems Inc.; FotoFinder Systems GmbH; GE HealthCare; Koninklijke Philips N.V.; Longport, Inc.; Michelson Diagnostics Ltd (MDL); VisualSonics

The rising incidence of skin cancer, the growing prevalence of skin disorders, and technological advancements are major factors driving the market's growth. According to the American Academy of Dermatology Association,  the most prevalent type of cancer in the U.S. is skin cancer, affecting around 9,500 individuals daily. It is predicted that one in every five Americans develops skin cancer during their lifetime, with over 5.4 million cases managed annually in the country.

Technological advancements are a significant driver in the U.S. market. For instance, In April 2024, Lumisight (pegulicianine) was approved by the FDA for use in adults with breast cancer. This fluorescent imaging drug is intended to help detect cancerous tissue inside the resection cavity after the primary tumor has been removed during a lumpectomy. Lumisight is given to patients as an intravenous injection before surgery. Lumisight is utilized alongside the Lumicell Direct Visualization System (DVS) or any other fluorescence imaging equipment that has received FDA approval for employment with pegulicianine in breast lumpectomy procedures.

Innovations such as high-resolution imaging, AI integration, 3D visualization, optical coherence tomography, digital photography, and high-frequency ultrasound have significantly enhanced dermatologists' diagnostic capabilities. For instance, In April 2024, researchers from Stanford Medicine discovered that artificial intelligence, particularly deep learning-based computer algorithms, enhances the accuracy of skin cancer diagnoses among healthcare professionals. Furthermore, In January 2024, US FDA approved the innovative DermaSensor, the first AI-powered tool for diagnosing over 200 types of skin cancer, including melanoma and other common carcinomas. Utilizing AI-driven spectroscopy, DermaSensor offers real-time, precise detection by analyzing lesions at the cellular level. This approval was based on a study led by the Mayo Clinic involving more than 1000 patients, confirming the device's effectiveness.

The public health programs offered by the American Academy of Dermatology (AAD) are significantly driving the market growth. Recent statistics suggest that about 20% of Americans will face skin cancer during their lives, with around 9,500 new cases diagnosed daily in the U.S. The AAD's skin cancer awareness education and public awareness campaigns are helping to increase public understanding of the importance of early detection and prevention of skin cancer. This heightened awareness drives the demand for dermatology imaging devices that can detect skin cancer early on, such as digital photographic imaging systems and optical coherence tomography (OCT) devices. The AAD's exclusive summer camp provides kids with chronic dermatological conditions and an exceptional camping experience, including medical support. The SPOT Skin Cancer initiative aims to raise awareness about skin cancer. Through teaching the public about ways to lower their risk of skin cancer and how to detect it early, they hope to alter habits and save lives.

The growing demand for minimally invasive dermatology procedures such as cryosurgery, laser surgery, radiofrequency surgery, chemical peels, microdermabrasion, micro needling, injectable therapies is driving the demand for dermatology imaging devices that can provide high-resolution images of the skin without the need for invasive procedures. Patients increasingly seek non-invasive diagnostic and treatment options to avoid the risks and discomfort associated with traditional invasive procedures. This shift towards minimally invasive approaches is further fueled by increased awareness about skin health, particularly the early detection of skin cancers, and the growing focus on cost-effective and patient-centric care. As a result, the demand for dermatology imaging devices that can deliver accurate, non-invasive diagnostic capabilities is rising, driving the market growth.

U.S. Dermatology Imaging Devices Market By Modality Insights

Based on modality, the dermatoscope segment led the market with the largest revenue share of 41.18% in 2023. Dermatoscopes provide dermatologists with a magnified and illuminated view of skin lesions, enabling them to identify characteristic patterns and structures that are not visible to the naked eye. This enhanced visualization improves diagnostic accuracy, particularly in differentiating benign and malignant skin lesions, reducing the need for unnecessary biopsies. Continuous improvements in dermatoscope technology, such as higher resolution, better illumination, and integration with digital imaging, have further enhanced their diagnostic capabilities.

The digital photographic imaging market is growing at the fastest CAGR over the forecast period. The growth of this segment is attributed to the ease of availability of smartphones, which allow capturing high-quality images of skin lesions, and handheld cameras with high-resolution transcripts of the image into a document of the patient's condition. In addition, the rise in skin cancer cases and the growing demand for non-invasive diagnostic procedures are also driving the growth of this segment. For instance, the MoleScope, FotoFinder, and Canfield VISIA are some of the digital photographic imaging devices used in the U.S. market, providing high-resolution skin images and allowing dermatologists to identify and track changes in the skin over time.

U.S. Dermatology Imaging Devices Market By Application Insights

Based on application, the skin cancer segment led the market with the largest revenue share of 48.24% in 2023. This was due to the higher prevalence and increased awareness of skin cancers. For instance, the American Cancer Society reports that in the U.S., skin cancers, primarily basal and squamous cell types, are the most prevalent form of cancer. Around 5.4 million cases are diagnosed annually, affecting approximately 3.3 million individuals, with basal cell cancers accounting for about 8 out of 10 cases. Squamous cell cancers are less frequent. The increasing incidence of skin cancer is expected to drive the demand for dermatology imaging devices. Technological advancements, such as optical coherence tomography (OCT) and confocal microscopy, are transforming the diagnosis of skin disorders by providing high-resolution images of skin layers in a non-invasive procedure.

The plastic and reconstructive surgery segment is anticipated to grow at a significant CAGR over the forecast period, driven by the rising demand for minimally invasive procedures and technological innovations in the field of plastic and reconstructive surgery. As the number of cosmetic surgeries continues to rise, there is a growing need for accurate imaging technologies to achieve optimal results. According to the American Society of Plastic Surgeons data, the number of cosmetic and reconstructive procedures performed in the United States increased significantly in 2022, with a total of 26.2 million procedures. This represents a 19% increase since 2019.

U.S. Dermatology Imaging Devices Market By End Use Insights

Based on end use, the hospital segment accounted for the largest revenue share of 44.0% in 2023. This is due to the widespread adoption of advanced dermatology imaging devices in hospitals, which enable dermatologists to accurately diagnose and effectively treat various skin conditions, including skin cancer. Hospitals employ highly trained and experienced dermatologists and imaging technicians, ensuring optimal utilization of these advanced technologies. They have the necessary infrastructure, resources, and expertise to provide patients with comprehensive diagnosis, treatment, and follow-up care. For Instance, in March 2024, the renewed collaboration between GE HealthCare and Hartford HealthCare is expected to strengthen the hospital segment of the market further, as it ensures that Hartford HealthCare continues to have access to GE HealthCare's advanced dermatology imaging technologies, enhancing its ability to provide high-quality care to patients.

U.S. Dermatology Imaging Devices Market Share, By End Use, 2023 (%)

The dermatology centers segment is expected to experience at a significant CAGR during the forecast period. This growth can be attributed to the increasing popularity of dermatology centers among patients seeking treatment for skin-related issues. These centers offer specialized care and expertise in skin-related issues, which not always be available in hospitals. For instance, dermatology centers utilize advanced imaging technologies such as dermatoscopes and digital photographic imaging systems to diagnose and treat various skin conditions. These devices provide high-resolution images of the skin, enabling dermatologists to identify characteristic patterns and structures that are not visible to the naked eye.

U.S. Dermatology Imaging Devices Market Recent Developments

  • In June 2024, the U.S. FDA has granted Breakthrough Device Designation to Enspectra Health’s cutting-edge AI-powered VIO Skin Platform. This platform combines the FDA-cleared VIO technology with VIO.ai NMSC software, aiming to aid physicians in assessing lesions suspected of being basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) in selected high-risk populations

  • In March 2024, EMZ Partners portfolio company FotoFinder Systems, recognized as a global leader in skin imaging solutions, finalized an agreement to acquire DermLite, manufacturer of handheld dermatoscopes. This acquisition represents EMZ Partners' first investment in the U.S.

  • In January 2024, GE HealthCare had announced an agreement to acquire IMACTIS, a French company specializing in computed tomography (CT) interventional guidance technology. The acquisition will strengthen GE HealthCare's interventional guidance offerings, providing more accurate and efficient procedures for interventional radiologists and hospitals

  • In June 2023, DeepX Diagnostics, a company specializing in teledermatology and skin cancer diagnostics, has received approval from the US Food and Drug Administration (FDA) for its digital dermatoscopy device, DermoSight. This approval allows DeepX Diagnostics to offer teledermatology screening for suspicious skin cancer lesions in the United States. This marks the company’s entry into the US market following its successful deployment in Europe, where it has already been used to assess over 180,000 skin lesions in pharmacies and primary care clinics

Some of the prominent players in the U.S. dermatology imaging devices market include:

  • Caliber Imaging and Diagnosis.
  • Canfield Scientific, Inc.
  • Clarius
  • Cortex Technology
  • Courage+Khazaka electronic GmbH
  • Comp6
  • DermLite
  • DRAMIŃSKI S. A.
  • e-con Systems Inc.
  • FotoFinder Systems GmbH
  • GE HealthCare
  • Koninklijke Philips N.V.
  • Longport, Inc.
  • Michelson Diagnostics Ltd (MDL)
  • VisualSonics

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. dermatology imaging devices market

Modality

  • Digital Photographic Imaging
  • Optical Coherence Tomography (OCT)
  • Dermatoscope
  • High Frequency Ultrasound
  • Others

Application

  • Skin Cancers
  • Inflammatory Dermatoses
    • Skin psoriasis
    • Eczema (Atopic dermatitis)
    • Others
  • Plastic & Reconstructive Surgery
  • Others

End Use

  • Hospitals
  • Dermatology centers
  • Specialty Clinics

Regional

  • West
  • Midwest
  • Northeast
  • Southwest
  • Southeast

Frequently Asked Questions

The U.S. dermatology imaging devices market size was exhibited at USD 815.55 million in 2023 and is projected to hit around USD 2,898.51 million by 2033, growing at a CAGR of 13.52% during the forecast period 2024 to 2033.

The U.S. dermatology imaging devices market is expected to grow at a compound annual growth rate of 13.52% from 2024 to 2033 to reach USD 2,898.51 million by 2033.

Dermatoscope dominated the U.S. dermatology imaging devices market with a share of 41.18% in 2023 as it offers dermatologists and healthcare providers a non-invasive and highly effective method for examining skin lesions and conditions.

Some key players operating in the U.S. dermatology imaging devices market include Canfield Scientific, Inc.; FotoFinder Systems GmbH; e-con Systems Inc.; Courage+Khazaka electronic GmbH; Longport, Inc.; Cortex Technology; DRAMIŃSKI S. A.; GE HealthCare; VisualSonics; Clarius; Koninklijke Philips N.V.; Michelson Diagnostics Ltd (MDL); Caliber Imaging and Diagnosis.; and DermLite

Key factors that are driving the market growth include technological advancements in high-resolution imaging systems, increasing prevalence of skin disorders necessitating accurate diagnostics, and expanding adoption of digital and AI-integrated dermatoscopes for enhanced diagnostic accuracy and efficiency.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope

1.2. Segment Definitions

1.2.1. Modality

1.2.2. Application

1.2.3. End use

1.2.4. Estimates and forecasts timeline

1.3. Research Methodology

1.4. Information Procurement

1.4.1. Purchased database

1.4.2. internal database

1.4.3. Secondary sources

1.4.4. Primary research

1.5. Information or Data Analysis

1.5.1. Data analysis models

1.6. Market Formulation & Validation

1.7. Model Details

1.7.1. Commodity flow analysis (Model 1)

1.7.2. Volume price analysis (Model 2)

1.8. List of Secondary Sources

1.9. List of Primary Sources

1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook

2.2. Segment Outlook

2.2.1. Modality outlook

2.2.2. Application outlook

2.2.3. End use outlook

2.3. Competitive Insights

Chapter 3. U.S. Dermatology Imaging Devices Market Variables, Trends & Scope

3.1. Market Lineage Outlook

3.1.1. Parent market outlook

3.1.2. Related/ancillary market outlook

3.2. Market Dynamics

3.2.1. Market driver analysis

3.2.1.1. Rising incidence of skin cancer

3.2.1.2. Growing prevalence of skin disorders

3.2.1.3. Technological Advancements

3.2.1.4. Growing demand for minimal invasive dermatology procedures

3.2.2. Market restraint analysis

3.2.2.1. High cost of dermatology imaging devices

3.3. U.S. Dermatology Imaging Devices Market Analysis Tools

3.3.1. Industry Analysis - Porter’s

3.3.1.1. Supplier power

3.3.1.2. Buyer power

3.3.1.3. Substitution threat

3.3.1.4. Threat of new entrant

3.3.1.5. Competitive rivalry

3.3.2. PESTEL Analysis

3.3.2.1. Political landscape

3.3.2.2. Technological landscape

3.3.2.3. Economic landscape

Chapter 4. U.S. Dermatology Imaging Devices Market: Modality Estimates & Trend Analysis

4.1. Modality Market Share, 2024 & 2033

4.2. Segment Dashboard

4.3. U.S. Dermatology Imaging Devices Market by Modality Outlook

4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033

4.4.1. U.S. Dermatology Imaging Devices

4.4.1.1. Market estimates and forecasts 2021 to 2033

4.4.1.2. Digital Photographic Imaging

4.4.1.2.1. Market estimates and forecasts 2021 to 2033

4.4.1.3. Optical Coherence Tomography (OCT)

4.4.1.3.1. Market estimates and forecasts 2021 to 2033

4.4.1.4. Dermatoscope

4.4.1.4.1. Market estimates and forecasts 2021 to 2033

4.4.1.5. High Frequency Ultrasound

4.4.1.5.1. Market estimates and forecasts 2021 to 2033

4.4.1.6. Others

4.4.1.6.1. Market estimates and forecasts 2021 to 2033

Chapter 5. U.S. Dermatology Imaging Devices Market: Application Estimates & Trend Analysis

5.1. Application Market Share, 2024 & 2033

5.2. Segment Dashboard

5.3. U.S. Dermatology Imaging Devices Market by Application Outlook

5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033

5.4.1. Skin Cancers

5.4.1.1. Market estimates and forecasts 2021 to 2033

5.4.2. Inflammatory Dermatoses

5.4.2.1. Market estimates and forecasts 2021 to 2033

5.4.2.2. Skin psoriasis

5.4.2.2.1. Market estimates and forecasts 2021 to 2033

5.4.2.3. Eczema (Atopic dermatitis)

5.4.2.3.1. Market estimates and forecasts 2021 to 2033

5.4.2.4. Others

5.4.2.4.1. Market estimates and forecasts 2021 to 2033

5.4.3. Plastic and Reconstructive Surgery

5.4.3.1. Market estimates and forecasts 2021 to 2033

5.4.4. Others

5.4.4.1. Market estimates and forecasts 2021 to 2033

Chapter 6. U.S. Dermatology Imaging Devices Market: End Use Estimates & Trend Analysis

6.1. End Use Market Share, 2024 & 2033

6.2. Segment Dashboard

6.3. U.S. Dermatology Imaging Devices Market by End Use Outlook

6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033

6.4.1. Hospitals

6.4.1.1. Market estimates and forecasts 2021 to 2033

6.4.2. Dermatology centers

6.4.2.1. Market estimates and forecasts 2021 to 2033

6.4.3. Specialty Clinics

6.4.3.1. Market estimates and forecasts 2021 to 2033

Chapter 7. U.S. Dermatology Imaging Devices Market: Region Estimates & Trend Analysis

7.1. Regional Market Share, 2024 & 2033

7.2. U.S. Dermatology Imaging Devices Market by Region Outlook

7.3. Market Size & Forecasts and Trend Analyses, 2021 to 2033

7.3.1. West

7.3.1.1. Market estimates and forecasts 2021 to 2033

7.3.2. Midwest

7.3.2.1. Market estimates and forecasts 2021 to 2033

7.3.3. Northeast

7.3.3.1. Market estimates and forecasts 2021 to 2033

7.3.4. Southwest

7.3.4.1. Market estimates and forecasts 2021 to 2033

7.3.5. Southeast

7.3.5.1. Market estimates and forecasts 2021 to 2033

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants

8.2. Company/Competition Categorization

8.3. Vendor Landscape

8.3.1. List of key distributors and channel partners

8.3.2. Key customers

8.3.3. Key company heat map analysis, 2024

8.4. Company Profiles

8.4.1. Canfield Scientific, Inc.

8.4.1.1. Company overview

8.4.1.2. Financial performance

8.4.1.3. Product benchmarking

8.4.1.4. Strategic initiatives

8.4.2. FotoFinder Systems GmbH

8.4.2.1. Company overview

8.4.2.2. Financial performance

8.4.2.3. Product benchmarking

8.4.2.4. Strategic initiatives

8.4.3. e-con Systems Inc.

8.4.3.1. Company overview

8.4.3.2. Financial performance

8.4.3.3. Product benchmarking

8.4.3.4. Strategic initiatives

8.4.4. Courage+Khazaka electronic GmbH

8.4.4.1. Company overview

8.4.4.2. Financial performance

8.4.4.3. Product benchmarking

8.4.4.4. Strategic initiatives

8.4.5. Longport, Inc.

8.4.5.1. Company overview

8.4.5.2. Financial performance

8.4.5.3. Product benchmarking

8.4.5.4. Strategic initiatives

8.4.6. Cortex Technology

8.4.6.1. Company overview

8.4.6.2. Financial performance

8.4.6.3. Product benchmarking

8.4.6.4. Strategic initiatives

8.4.7. DRAMIŃSKI S. A.

8.4.7.1. Company overview

8.4.7.2. Financial performance

8.4.7.3. Product benchmarking

8.4.7.4. Strategic initiatives

8.4.8. GE HealthCare

8.4.8.1. Company overview

8.4.8.2. Financial performance

8.4.8.3. Product benchmarking

8.4.8.4. Strategic initiatives

8.4.9. VisualSonics

8.4.9.1. Company overview

8.4.9.2. Financial performance

8.4.9.3. Product benchmarking

8.4.9.4. Strategic initiatives

8.4.10. Clarius

8.4.10.1. Company overview

8.4.10.2. Financial performance

8.4.10.3. Product benchmarking

8.4.10.4. Strategic initiatives

8.4.11. Koninklijke Philips N.V.

8.4.11.1. Company overview

8.4.11.2. Financial performance

8.4.11.3. Product benchmarking

8.4.11.4. Strategic initiatives

8.4.12. Michelson Diagnostics Ltd (MDL)

8.4.12.1. Company overview

8.4.12.2. Financial performance

8.4.12.3. Product benchmarking

8.4.12.4. Strategic initiatives

8.4.13. Caliber Imaging and Diagnosis.

8.4.13.1. Company overview

8.4.13.2. Financial performance

8.4.13.3. Product benchmarking

8.4.13.4. Strategic initiatives

8.4.14. DermLite

8.4.14.1. Company overview

8.4.14.2. Financial performance

8.4.14.3. Product benchmarking

8.4.14.4. Strategic initiatives

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-img Cross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers